Allergy Immunotherapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The allergy immunotherapy market size is estimated at USD 2.67 billion in 2026, and is expected to reach USD 3.72 billion by 2031, at a CAGR of 6.85% during the forecast period (2026-2031). This report is Segmented by Immunotherapy Type (Subcutaneous Immunotherapy and Sublingual Immunotherapy (SLIT)), and More), Allergy Type (Allergic Rhinitis, Allergic Asthma, and More), Formulation (Injectable Suspensions, and More), Distribution Channel (Direct-To-Physician Sales, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Allergy Immunotherapy Market Trends and Insights

Growing Global Burden & Economic Cost of Respiratory and Food Allergies

Direct medical spending and productivity losses from food, nasal, and asthma-linked allergies now exceed USD 110 billion in the United States, amplifying payer appetite for interventions that promise durable relief. Global prevalence continues to climb as urbanization and lifestyle shifts intensify exposure, pushing peanut allergy alone to affect 1.5 million U.S. children. Biologic therapies carry five-figure annual costs, positioning long-course immunotherapy as a comparatively economical option for health systems. Employers recognize that unmanaged allergies drive absenteeism, especially among school-age children whose reactions disrupt parental work schedules. The magnitude of this economic drag supplies momentum for broader reimbursement of disease-modifying therapies.

Expedited Approvals & Reimbursement of SLIT Tablets in US, EU & Japan

Between 2024 and 2025 the FDA, EMA, and PMDA approved multiple pediatric and adult SLIT indications, shrinking regulatory bottlenecks and sharpening the competitive edge of tablet formats. Concurrent payer rule changes added Relative Value Units for home-based dosing and clarified CPT billing, trimming administrative hurdles. These synchronized updates lower out-of-pocket costs and accelerate commercial uptake, especially among pediatric cohorts now eligible for earlier treatment. The trajectory signals a virtuous cycle where regulatory validation feeds payer confidence and vice versa.

Low Diagnosis & Therapy Uptake in Low-Income Regions

Many emerging economies lack allergists, diagnostic labs, and reimbursement pathways, forcing patients to rely on over-the-counter drugs that mask rather than resolve disease. Import tariffs and cold-chain challenges inflate extract costs. Public health funding favors infectious disease, delaying large-scale allergy programs. These structural gaps hold back penetration despite rising prevalence and documented productivity losses.

Other drivers and restraints analyzed in the detailed report include:

• Inclusion of AIT in Value-Based Care Frameworks
• Home-Based Self-Administration Platforms Improving Adherence
• Product-Specific Anaphylaxis Risk & Safety-Monitoring Costs

Segment Analysis

In 2025 Subcutaneous Immunotherapy captured 44.55% Allergy Immunotherapy market share, yet Sublingual Immunotherapy is forecast to outpace with a 15.25% CAGR. The rise stems from home dosing that erases weekly clinic visits, a compelling benefit for working adults and parents. ALK-Abelló’s tablet revenues advanced 24% year over year in 2024, signaling strong uptake. SCIT retains an edge where multiple allergen sensitivities demand custom mixes, but compliance hurdles curb growth. Epicutaneous and oral modalities remain developmental, positioning SLIT as the near-term disruptor of choice.

Digital pharmacies integrate testing, formulation, shipping, and monitoring into single-fee subscriptions that resonate with digitally fluent consumers. Regulatory clearance for virtual initiation visits legitimizes these models. Clinics focused on SCIT grapple with lower revenue per hour and liability risk, pushing some to refer patients to hospital settings. While EPIT and OIT may disrupt long-term, SLIT dominates the growth story through 2031.

Allergic Rhinitis maintained 47.53% of the Allergy Immunotherapy market size in 2025, yet Food Allergy is set to climb at a 16.85% CAGR following PALFORZIA’s toddler label and supportive NIH data showing 100% tolerance in children completing at-home peanut OIT. Biologic approvals targeting food allergy amplify systemic attention and payer openness. Asthma and venom segments remain clinically important niches, while atopic dermatitis emerges as a pipeline frontier.

Peanut, egg, and milk allergies draw investment as early intervention may induce lifelong tolerance. The commercialization of low-cost, non-proprietary OIT regimens threatens branded incumbents, potentially reshaping competitive dynamics. Meanwhile rhinitis growth decelerates as biologics compete for moderate-to-severe cases.

Complete Report Scope:

• By Immunotherapy Type
  • Subcutaneous Immunotherapy (SCIT)
  • Sublingual Immunotherapy (SLIT)
  • Epicutaneous Immunotherapy (EPIT)
  • Oral Immunotherapy (OIT)
• By Allergy Type
  • Allergic Rhinitis
  • Allergic Asthma
  • Food Allergy
  • Venom Allergy
  • Atopic Dermatitis
  • Others
• By Formulation
  • Injectable Suspensions
  • Sublingual Drops
  • Sublingual Tablets
  • Transdermal Patches
• By Distribution Channel
  • Direct-to-Physician Sales
  • Retail & Hospital Pharmacies
  • E-commerce / Mail-Order
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America contributed 42.53% of 2025 revenue, buoyed by Medicare reimbursement updates and dense allergist networks. FDA pediatric label expansions unlocked new cohorts and consolidated the United States as the single largest Allergy Immunotherapy market. Canadian approvals pending as of 2025 and Mexican private-insurance uptake maintain regional momentum, though biologic competition tempers long-term growth.

Asia-Pacific is projected to record a 15.21% CAGR, the fastest among regions. Japan’s 2024 approval of ITULAZAX for cedar pollen meets a widespread seasonal burden, with Torii Pharmaceutical data showing year-over-year efficacy gains. Chinese authorities require bridging trials for tablets, pushing initial focus to SCIT, while India’s 2025 launch of a house dust mite tablet leverages local distribution heft. Rising disposable income and urban allergy prevalence drive demand across South Korea and Australia.

Europe remains a mature but vital market, accounting for 71% of ALK-Abelló revenue in 2024. Germany tops country sales, supported by Therapieallergene-Verordnung provisions that sustain named-patient supply during regulatory review. EMA approval of neffy in 2024 adds anaphylaxis management to the regional portfolio. Pricing pressures and generic entrants limit pricing power, yet broad reimbursement keeps volumes stable. Middle East and Africa and South America trail due to sparse allergist networks and limited public funding. Pilot projects hint at future upside but near-term contributions remain modest.

List of Companies Covered in this Report:

• Aimmune Therapeutics (Nestle)
• ALK-Abello
• Allergy Therapeutics plc
• Allovate Therapeutics
• Biomay
• Camallergy
• Circassia Group plc
• DBV Technologies
• DESENTUM Oy
• HAL Allergy Group
• HollisterStier Allergy (Jubilant Pharma)
• Inmunotek S.L.
• LETI Pharma
• Merck
• Prota Therapeutics
• Stallergenes Greer
• Torii Pharmaceutical
• Tunitas Therapeutics
• Vida Pharmaceuticals
• Zhejiang Wolwo Biopharmaceutical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support